Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by diadon1945on Jan 30, 2008 1:17pm
270 Views
Post# 14290236

RE: FEB.20-22 , 2008

RE: FEB.20-22 , 2008Good point Brox! And if you have not looked at the interim results news item posted on the company website you should have a look. The results on the first 4 patients were not only good they were excellent. I expect more of the same from the full 12 patient study....and they have already gone ahead into the phase IIb, which they would not have done if the results were not good in the phase IIa study! The general market sucks....this company has been flying under the radar...but I expect great results to be announced at the International Stroke Conference(FEB.20-22) and I would not be surprised to see some international investment to follow. If you look at the schedule of events you will see a large number of of Bio-partnering type meetings. And stroke,TBI and MS indication studies will be underway soon and these are all areas that need better treatments with market potential of over $10 billion each.
Bullboard Posts